First Word Pharma reports that Androgel maker AbbVie has abandoned its plan to buy out pharmaceutical maker Shire. AbbVie says the bid for Shire was withdrawn in light of recent U.S. tax law changes. As a result of the failed deal, AbbVie will have to pay $1.6 billion to Shire and will be unable to make another offer to purchase the company for at least a year.
The Androgel maker was recently in the news over ...
continue reading...
A recent story posted by MedlinePlus notes new guidelines from the Endocrine Society. The guidelines say no testosterone therapy for women as the benefits are not clear and the risks of testosterone therapy are unknown in women.
Although there is some research indicating that testosterone therapy may be helpful to sexual function in menopausal women, a statement by the Endocrine Society says there are too many unanswered questions about the risks of testosterone therapy in ...
continue reading...A possible link between testosterone therapy and increased heart risks has prompted much debate recently. A recent Bloomberg news article talks about ongoing discussions over the safety and effectiveness of testosterone therapy drugs.
One study, published in January of 2014, showed that testosterone therapy may lead to an increased risk of heart attack in men aged 65 and older, as well as in younger men with a history of heart disease. Of a group of ...
continue reading...Phthalates, common chemicals found in many plastics and consumer products may have a negative effect on testosterone levels in men, women, and children. An article in MedlinePlus reports of a University of Michigan study which examined the effects of exposure to phthalates on testosterone levels.
The study, published in the Journal of Clinical Endocrinology & Metabolism, found that higher level exposure to the chemicals was associated with an 11 to 24 percent ...
continue reading...Scientists at the University of North Texas Health Science Center have released a study citing links between testosterone therapy and cognitive issues in Caucasian men. The study focused on the effect of testosterone-replacement therapy on men suffering from oxidative stress, a condition correlated with blood clots. According to the article, oxidative stress can in turn cause testosterone therapy to have additional side-effects.
The study indicates that in Caucasian males ...
continue reading...
The Food and Drug Administration (FDA) recently issued a new safety alert stating that men who use testosterone therapy products are at an increased risk for venous blood clots, a condition referred to as venous thromboembolism (VTE). The FDA is requiring all manufacturers of testosterone therapy products to include on labels a general warning about the heightened VTE risks.
Venous blood clots are as they sound — blood clots that occur in the veins. ...
continue reading...
